BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment

Inclusion Criteria: * Written informed consent of the patient with regard to the pseudonymized documentation of his/her data in the frame of this non-interventional study * Legally capable patient ≥ 18 years of age (no upper limit) * Metastatic colorectal carcinoma with BRAFV600E-mutation, pretreated with systemic therapy * Decision was taken to treat the patient with the doublet therapy (encorafenib and cetuximab) in accordance with the current SmPC and by prescription; this decision was taken prior to and independent from the inclusion into the study; * Treatment with the doublet therapy (encorafenib plus cetuximab) has been started ≤ 3 months prior to providing written informed consent for this study or is planned to be started in the near future. Exclusion Criteria: * More than 2 prior systemic regimens in the metastatic setting (adjuvant systemic therapy with relapse ≤ 6 months will be counted as metastatic treatment line; maintenance treatment will not be counted as separate metastatic treatment line) * Prior treatment with any RAF-inhibitor or MEK-inhibitor. * Presence of any contraindication with regard to the doublet therapy (encorafenib plus cetuximab) as specified in the corresponding SmPCs * Current or upcoming participation in an interventional clinical trial * Current or upcoming systemic treatment of any other tumor than metastatic colorectal carcinoma * Prisoners or persons who are compulsorily detained (involuntarily incarcerated).